Background

The myeloma overexpressed gene (MYEOV) plays a critical role in tumorigenesis in a variety of cancers. However, little is known of the prognosis and immune infiltration associated with MYEOV in non-small cell lung cancer (NSCLC).

Methods

We used several databases (Oncomine, TCGA, and GEO) to analysis the expression, prognosis, and immune infiltration, associated with MYEOV in NSCLC. We also used RT-qPCR and immunohistochemistry to investigate the expression and prognosis of MYEOV in NSCLC.

Results

Compared with normal tissues, high MYEOV expression in NSCLC was observed in Oncomine database, and was validated in the TCGA database. High MYEOV expression was significantly associated with different subtypes of NSCLC. Moreover, high MYEOV expression was closely related with a poorer overall survival in NSCLC in TCGA cohort, and was validated in GEO database. Simultaneously, high expression of MYEOV correlates with clinical relevance of NSCLC. Specifically, MYEOV expression was negatively correlated with infiltrating levels of tumor purity and B cells in LUAD. MYEOV expression was negatively correlated with infiltrating levels of tumor purity, and positively associated with CD8 + T cells, CD4 + T cells, dendritic cells, and neutrophils in LUSC. GSEA also revealed that high MYEOV expression were enriched in certain cancer-specific pathways. In addition, RT-qPCR and immunohistochemistry showed MYEOV expression was higher in NSCLC compared to the normal tissues. Finally, high MYEOV expression was closely related with poorer overall survival of NSCLC in an independent validation cohort.

Conclusion

Our analyses indicate that MYEOV can be used as a prognostic biomarker for determining prognosis and immune infiltration in NSCLC.

中文翻译：

---

MYEOV高表达反映了非小细胞肺癌的预后不良

背景

骨髓瘤过度表达基因（MYEOV）在多种癌症的肿瘤发生中起着至关重要的作用。然而，对于非小细胞肺癌（NSCLC）中与MYEOV相关的预后和免疫浸润知之甚少。

方法

我们使用了多个数据库（Oncomine，TCGA和GEO）来分析与NSCLC中MYEOV相关的表达，预后和免疫浸润。我们还使用RT-qPCR和免疫组化研究了MYEOV在非小细胞肺癌中的表达和预后。

结果

与正常组织相比，在Oncomine数据库中观察到了NSCLC中高MYEOV表达，并在TCGA数据库中得到了验证。MYEOV高表达与NSCLC的不同亚型显着相关。而且，MYEOV高表达与TCGA队列中NSCLC较差的总体生存率密切相关，并已在GEO数据库中得到验证。同时，MYEOV的高表达与NSCLC的临床相关性相关。具体而言，MYEOV表达与LUAD中肿瘤纯度和B细胞的浸润水平负相关。MYEOV表达与肿瘤纯度的浸润水平呈负相关，与LUSC中的CD8 + T细胞，CD4 + T细胞，树突状细胞和中性粒细胞呈正相关。GSEA还显示，MYEOV高表达在某些癌症特异性途径中富集。此外，RT-qPCR和免疫组化显示，与正常组织相比，NSCLC中的MYEOV表达更高。最后，在独立的验证队列中，MYEOV的高表达与NSCLC整体生存期较差密切相关。

结论

我们的分析表明，MYEOV可用作确定NSCLC的预后和免疫浸润的预后生物标志物。